1BSL01AE Stock Overview
Biotika a.s. operates as a pharmaceutical manufacturing company in Slovakia and internationally.
+ 1 more risk
Price History & Performance
|Historical stock prices|
|Current Share Price||€38.60|
|52 Week High||€42.00|
|52 Week Low||€37.20|
|1 Month Change||0%|
|3 Month Change||-1.03%|
|1 Year Change||-1.03%|
|3 Year Change||33.10%|
|5 Year Change||10.29%|
|Change since IPO||-95.08%|
Recent News & Updates
Should You Buy Biotika a.s. (BSSE:1BSL01AE) For Its Dividend?
Is Biotika a.s. (BSSE:1BSL01AE) a good dividend stock? How can we tell? Dividend paying companies with growing...
|1BSL01AE||SK Pharmaceuticals||SK Market|
Return vs Industry: 1BSL01AE underperformed the SK Pharmaceuticals industry which returned 2.9% over the past year.
Return vs Market: 1BSL01AE underperformed the SK Market which returned 3.6% over the past year.
|1BSL01AE Average Weekly Movement||n/a|
|Pharmaceuticals Industry Average Movement||5.8%|
|Market Average Movement||5.5%|
|10% most volatile stocks in SK Market||10.4%|
|10% least volatile stocks in SK Market||2.9%|
Stable Share Price: Insufficient data to determine 1BSL01AE's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine 1BSL01AE's volatility change over the past year.
About the Company
Biotika a.s. operates as a pharmaceutical manufacturing company in Slovakia and internationally. The company offers active pharmaceutical ingredients (API), including phenoxymethylpenicillin potassium, phenoxymethylpenicillin potassium granulated, phenoxymethylpenicillin calcium, and polymyxin B sulfate (non-sterile) substances; and pharmaceutical preparations for the human and veterinary applications. It is also involved in the contract manufacture of APIs comprising Gramicidin S hydrochlorid (non-sterile) and L-CYSTINE substances; and antibiotics.
Biotika Fundamentals Summary
|1BSL01AE fundamental statistics|
Is 1BSL01AE overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1BSL01AE income statement (TTM)|
|Cost of Revenue||€16.09m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||0.41|
|Net Profit Margin||4.55%|
How did 1BSL01AE perform over the long term?See historical performance and comparison
6.7%Current Dividend Yield
Is 1BSL01AE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 1BSL01AE?
Other financial metrics that can be useful for relative valuation.
|What is 1BSL01AE's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 1BSL01AE's PE Ratio compare to its peers?
|1BSL01AE PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
ADWYA Société ADWYA
524075 Albert David
ACTIVEFINE Active Fine Chemicals
532649 Nectar Lifesciences
Price-To-Earnings vs Peers: 1BSL01AE is expensive based on its Price-To-Earnings Ratio (93.5x) compared to the peer average (50.1x).
Price to Earnings Ratio vs Industry
How does 1BSL01AE's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 1BSL01AE is expensive based on its Price-To-Earnings Ratio (93.5x) compared to the European Pharmaceuticals industry average (18x)
Price to Earnings Ratio vs Fair Ratio
What is 1BSL01AE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||93.5x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1BSL01AE's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 1BSL01AE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 1BSL01AE (€38.6) is trading below our estimate of fair value (€47.23)
Significantly Below Fair Value: 1BSL01AE is trading below fair value, but not by a significant amount.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Biotika forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biotika has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine Biotika's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
How has Biotika performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1BSL01AE has high quality earnings.
Growing Profit Margin: 1BSL01AE's current net profit margins (4.6%) are lower than last year (12.9%).
Past Earnings Growth Analysis
Earnings Trend: 1BSL01AE's earnings have declined by 1.4% per year over the past 5 years.
Accelerating Growth: 1BSL01AE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 1BSL01AE had negative earnings growth (-82.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (18.2%).
Return on Equity
High ROE: 1BSL01AE's Return on Equity (1.5%) is considered low.
Discover strong past performing companies
How is Biotika's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 1BSL01AE's short term assets (€9.9M) exceed its short term liabilities (€2.8M).
Long Term Liabilities: 1BSL01AE's short term assets (€9.9M) exceed its long term liabilities (€918.2K).
Debt to Equity History and Analysis
Debt Level: 1BSL01AE has more cash than its total debt.
Reducing Debt: 1BSL01AE's debt to equity ratio has reduced from 29.8% to 0% over the past 5 years.
Debt Coverage: 1BSL01AE's debt is well covered by operating cash flow (51001.1%).
Interest Coverage: 1BSL01AE earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Biotika current dividend yield, its reliability and sustainability?
Dividend Score 1/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 1BSL01AE's dividend (6.74%) is higher than the bottom 25% of dividend payers in the SK market (1.13%).
High Dividend: 1BSL01AE's dividend (6.74%) is low compared to the top 25% of dividend payers in the SK market (6.82%).
Stability and Growth of Payments
Stable Dividend: 1BSL01AE has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 1BSL01AE has only been paying a dividend for 6 years, and since then payments have fallen.
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (448.6%), 1BSL01AE's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (6496.4%), 1BSL01AE's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Biotika has no CEO, or we have no data on them.
Experienced Management: 1BSL01AE's management team is considered experienced (3.2 years average tenure).
Experienced Board: 1BSL01AE's board of directors are considered experienced (4.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Biotika a.s.'s employee growth, exchange listings and data sources
- Name: Biotika a.s.
- Ticker: 1BSL01AE
- Exchange: BSSE
- Founded: 1953
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €37.951m
- Shares outstanding: 983.20k
- Website: https://www.biotika.sk
Number of Employees
- Biotika a.s.
- Slovenská Lupca 566
- Slovenská Lupca
- 976 13
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/10 00:00|
|End of Day Share Price||2022/05/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.